Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...

1. In this retrospective observational cohort study of children in St. Louis, those with the highest risk of firearm injury ...

1. In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was found to have good overall performance in predicting risk for ...

1. In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a significant improvement of constipation-related quality of life (QOL) in ...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced meaningful improvements in alertness, behavior, and communication. In a randomized ...

1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...